Ascendis Pharma A/S

NASDAQ:ASND

Biotechnology

Healthcare
$270.33 -0.02%

-$0.05 today

Market cap
$17.73B
Beta
0.39
P/E (TTM)
24.5
EPS (TTM)
$8.21
52W Low $160.86High $250.74

Volume 0.57M

Average 0.64M

ASND Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Ascendis Pharma A/SNASDAQ: ASND

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin widens to 91.2%

Gross margin was 91.2% in Q3 FY2026, up 1.7 pp from a year earlier. On a trailing-twelve-month basis it was 90.6%, up 3.8 pp year over year. Over 3 fiscal years it widened by 8.8 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
91.2%+0.6 pp QoQ
Last fiscal yearDec 2025
85.1%-2.7 pp YoY
LTMSep 2026
90.6%+3.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.7 pp——
1 year-2.7 pp——
3 years+8.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
85.1%
Year-over-year change
-2.7pp

Gross Margin vs competitors

How ASND compares with its peers on the latest reported figures

  • ASND's LTM Sep 2026 gross margin of 90.6% is the 3rd highest of the 10 companies compared; the peer median is 83.6%.
  • Its year-over-year change of +3.8 pp is the 2nd highest of 10, against a peer median of -1.4 pp.
  • Over three fiscal years its change of +8.8 pp compares with a peer median of -0.1 pp.
ASND Competitors Peer median
Gross Margin for ASND and competitors
Company Period LTM level YoY 3-year change
CORTCorcept Therapeutics IncorporatedLTM Jun 202698.3% -0.1 pp-0.4 pp
NBIXNeurocrine Biosciences, Inc.LTM Sep 202697.8% -0.6 pp-0.3 pp
ASNDAscendis Pharma A/SLTM Sep 202690.6% +3.8 pp+8.8 pp
STOKStoke Therapeutics, Inc.LTM Mar 202690.4% -9.1 pp+0.0 pp
UTHRUnited Therapeutics CorporationLTM Jun 202686.1% -2.8 pp-4.5 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202683.6% -1.6 pp-8.4 pp
INSMInsmed IncorporatedLTM Jun 202683.3% +7.6 pp+1.9 pp
XERSXeris Biopharma Holdings, Inc.LTM Mar 202681.6% +0.6 pp+2.2 pp
SEPNSepterna, Inc.LTM Sep 202679.9% -20.1 pp—
BMRNBioMarin Pharmaceutical Inc.LTM Sep 202679.9% -1.4 pp+1.1 pp
MBXMBX Biosciences, Inc. Common StockFY2025— ——
Peer median (excluding ASND) 83.6%-1.4 pp-0.1 pp

Competitors are the stored peer set for ASND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.78M51.17M266.72M363.64M691.71M
Cost of Revenue3.52M12.14M44.4M44.26M103.18M
Gross Profit4.26M39.04M222.32M319.38M588.53M
Gross Margin54.7%76.3%83.4%87.8%85.1%
Research & Development295.87M379.62M413.45M307M283.5M
Selling, General & Admin160.18M215.85M258.79M284.55M435.92M
Operating Expenses456.05M600.85M677.86M598.15M719.42M
Depreciation & Amortization15.39M17.96M18.91M17.71M17M
EBITDA(364.64M)(529.18M)(411.17M)(290.02M)(109.8M)
EBITDA Margin-4688.1%-1034.1%-154.2%-79.8%-15.9%
Operating Income(451.79M)(561.81M)(455.54M)(278.76M)(130.89M)
Operating Margin-5808.6%-1097.9%-170.8%-76.7%-18.9%
Interest Income692K7.43M16.86M14.36M14.7M
Interest Expense3.91M30.68M44.07M65.5M77.46M
Other Income / Expenses67.85M(16M)(18.6M)(94.48M)(73.37M)
Income Before Tax(383.94M)(577.82M)(474.14M)(373.24M)(204.26M)
Pre-Tax Margin-4936.3%-1129.1%-177.8%-102.6%-29.5%
Income Tax Expense(367K)5.38M7.3M4.84M14.78M
Net Income(383.58M)(583.19M)(481.45M)(378.08M)(219.03M)
Net Margin-4931.6%-1139.6%-180.5%-104.0%-31.7%
EPS (Basic)(7.00)(10.40)(8.55)(6.53)(3.62)
EPS (Diluted)(7.00)(10.40)(8.55)(6.53)(3.62)
Weighted Avg Shares54.77M56.07M56.29M57.89M60.61M
Weighted Avg Shares (Diluted)54.77M56.07M56.29M57.89M60.61M

Ascendis Pharma A/S

NASDAQ:ASND

Intrinsic Alpha fair value

Locked

Current Price

$270.33

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.